MedTrace Logo

Diagnostic and Prognostic Biomarkers of Sepsis

NCT04767893 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2021-02-23

No results posted yet for this study

Summary

This study aims to evaluate sepsis biomarkers as soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) and soluble urokinase plasminogen activator receptor (sUPAR) in diagnosis of sepsis in comparison to the traditional blood culture and C-reactive protein (CRP) and to evaluate the prognostic value of these biomarkers in comparison to sequential organ failure assessment score (SOFA score), Acute Physiology and Chronic Health Evaluation II ( APACHI score), 28 day mortality.

Conditions

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Nahed Fathallah, lecturer · Sohag University

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-14
Primary Completion
2020-12-01
Completion
2020-12-28

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04767893 on ClinicalTrials.gov